Skip to main content
PMC home page
Frontiers in Pediatrics logoLink to Frontiers in Pediatrics
. 2024 Jan 31;11:1260740. doi: 10.3389/fped.2023.1260740

Efficacy and safety of respiratory syncytial virus vaccination during pregnancy to prevent lower respiratory tract illness in newborns and infants: a systematic review and meta-analysis of randomized controlled trials

Juan Ma 1,2,3,4,†,#, Long Chen 5,†,#, ShiFang Tang 4, Yuan Shi 1,2,3,*
PMCID: PMC10864603  PMID: 38357264

Abstract

To evaluate the effectiveness and safety of respiratory syncytial virus (RSV) vaccination during pregnancy in preventing lower respiratory tract infection (LRTI) in infants and neonates, we conducted a systematic search of randomized controlled trials (RCTs) in five databases (PubMed, Embase and Cochrane Library, Web of Science, Cochrane Center Register of Controlled trial) until 1 May 2023. We performed a meta-analysis of the eligible trials using RevMan5.4.1 software. Our analysis included six articles and five RCTs. The meta-analysis revealed significant differences in the incidences of LRTI [risk ratio (RR): 0.64; 95% confidence interval (CI): 0.43, 0.96; p = 0.03)] and severe LRTI (RR: 0.37; 95% CI: 0.18, 0.79; p = 0.01) between the vaccine group and the placebo group for newborns and infants. These differences were observed at 90, 120, and 150 days after birth (p = 0.003, p = 0.05, p = 0.02, p = 0.03, p = 0.009, p = 0.05). At 180 days after birth, there was a significant difference observed in the incidence of LRTI between the two groups (RR: 0.43; 95% CI: 0.21, 0.90; p = 0.02). The safety results showed a significant difference in the incidence of common adverse events between the two groups (RR: 1.08; 95% CI: 1.04, 1.12; p < 0.0001). However, there was no significant difference observed in the incidence of serious adverse events (RR: 1.05; 95% CI: 0.97, 1.15; p = 0.23), common and serious adverse events (RR: 1.02; 95% CI: 0.96, 1.10; p = 0.23), or common and serious adverse events among pregnant women and newborns and infants (RR: 0.98; 95% CI: 0.93, 1.04; p = 0.52). In conclusion, maternal RSV vaccination is an effective and safe immunization strategy for preventing LRTI in postpartum infants, with greater efficacy observed within the first 150 days after birth.

Keywords: respiratory syncytial virus, vaccination, pregnancy, newborns and infants, efficiency, meta-analysis

1. Introduction

Respiratory syncytial virus (RSV) is a leading cause of hospitalization for lower respiratory tract diseases in infants worldwide. RSV is accountable for approximately 102,000 deaths annually from RSV infection worldwide, making it a prominent cause of death in infants under 6 months of age, particularly in low- and middle-income countries (1, 2). Severe lower respiratory tract illness associated with RSV is most prevalent between the months of March and June following birth. Studies have revealed that RSV is responsible for 50% of respiratory hospitalizations in children under 1 year of age, with approximately 60% of these cases affecting infants younger than 3 months (3–7). However, there is currently no approved RSV vaccine, which poses challenges in initiating timely vaccination against RSV between the ages of 3 and 6 months.

Maternal vaccination is an effective alternative to protect infants from viral infections. Vaccination of the mother results in an elevation of her antibody levels, and these antibodies are transferred to the fetus through the placenta, providing passive immunity for the first few months of the infant's life (1, 8–13). The World Health Organization has approved the vaccination of pregnant women to safeguard their babies from tetanus, diphtheria, pertussis, influenza, and SARS-CoV-2 (14–17). Based on this, we propose that maternal vaccination with RSV-associated vaccines could also be effective in protecting infants (18–21).

There have been advancements in RSV-related vaccines since the 1960s. After years of research, a breakthrough in the field of RSV vaccines has been achieved in 2022, following the successful completion of several phase III clinical trials. The membrane protein F of RSV has emerged as the primary target protein for RSV vaccine development in recent years (22–24). Previous studies have identified safety concerns with RSV vaccines in pregnant women, but the reasons for these issues are still unclear. This study aims to systematically evaluate the safety and efficacy of RSV vaccines in pregnant women, providing valuable evidence for clinical use.

2. Materials and methods

This systematic review and meta-analysis was registered in PROSPERO (CRD42019129316) prior to conducting the study search. It was conducted in adherence to the expected methodology of Cochrane intervention evaluation and presented in accordance with the recommendations of the preferred reporting project (PRISMA) guide for systematic review and meta-analysis (25).

2.1. Search strategy

A systematic retrieval was conducted on five databases (PubMed, Embase, the Cochrane Library, Web of Science, and Cochrane Center Register of Controlled trial) from their inception until 1 June 2023. The search terms used included vaccination, respiratory syncytial virus, pregnancy, newborns, and infants. More information on the search details can be found in Supplementary Tables S1–S5.

2.2. Selection criteria

The criteria for inclusion in the meta-analysis were as follows: (1) vaccination of pregnant women; (2) RSV vaccine administration; (3) comparison of RSV vaccine with placebo in randomized controlled trials (RCTs); and (4) reporting on the safety and efficacy of RSV. The exclusion criteria for the studies were as follows: (1) vaccination of non-pregnant women; (2) non-original studies, systematic reviews, meta-analyses, conference abstracts, letters, editorial comments, case reports, unpublished articles, and non-English articles; (3) studies involving animals or preclinical testing; (4) non-randomized controlled trials; and (5) outcomes that were not of interest.

2.3. Data extraction

The Cochrane Risk of Bias tool was utilized to evaluate the methodological quality of the included studies (26). The literature was independently screened by two individuals (JM and LC), and any disagreements were resolved through discussion or by involving a third person. The extracted data consisted of the first author's name, year of publication, country of study, study design, type of RCT bias risk assessment, sample size of the study subjects, grouping, baseline data, interventions, and outcome indicators. The main outcome measures encompassed medically attended lower respiratory tract illness, medically attended severe lower respiratory tract illness, adverse events in the maternal participants, severe adverse events in the maternal participants, adverse events in the infant participants, and severe adverse events in the infant participants. We conducted a thorough review of the included studies, original texts, and supplementary material to ensure that no data were overlooked.

2.4. Data analysis

The meta-analysis was conducted using RevMan 5.4.1 software. For categorical variables, the risk ratio (RR) was used as the effect index, while for continuity variables, the weighted mean difference (WMD) or standardized mean difference (SMD) was used. Each effect size was expressed with a 95% confidence interval (CI), and its point estimate was provided. The heterogeneity of the literature was assessed using the χ2 test. If p > 0.1 and I2 ≤ 50%, the fixed-effect model was employed. If p ≤ 0.1 and I2 > 50%, the source of heterogeneity was analyzed, and after excluding obvious clinical heterogeneity, the random-effects model was used to evaluate the source of heterogeneity. Sensitivity analysis was performed for both models. The significance level for the meta-analysis was set at α = 0.05, unless otherwise stated. Furthermore, a one-way sensitivity analysis was conducted to assess the impact of the included studies on the pooled outcome for outcomes with significant heterogeneity. Publication bias was assessed visually using funnel plots generated by Review Manager 5.4.1 version (Cochrane Collaboration, Oxford, UK), and Egger's regression tests were conducted using Stata 15.1 version (Stata Corp, College Station, TX, USA) for outcomes with three or more included studies. A p-value < 0.05 was considered statistically significant for publication bias.

3. Results

3.1. Characteristics of the included studies

The flowchart of the system search and selection process is shown in Figure 1. A total of 642 relevant articles were obtained from PubMed (n = 196), Embase (n = 187), Cochrane Library (n = 31), Web of Science (n = 228), and Cochrane Center Register of Cochrane Controlled Trial (n = 31). After removing duplicates, 456 titles and abstracts were reviewed. Finally, six full-text articles were included for the pooled analysis, involving 17,230 pregnant women (10,226 vaccinated vs. 7,004 placebo) and 16,878 newborns (10,041 vaccinated vs. 6,837 placebo). Six of these studies were multicenter randomized controlled trials (27–32, 33, 34, 35). Four studies (27, 29–31) included the primary outcome index: the number of infants with lower respiratory tract infection (LRTI). Two of these studies (27, 31) also collected data on the number of infants with LRTI at 90, 120, 150, and 180 days after birth. Five articles (27–29, 31, 32) analyzed the safety indicators of vaccine use, including common and serious adverse reactions in mothers and infants. One article (30) examined the use of antibiotics after birth in infants whose mothers received RSV vaccine during pregnancy. Table 1 summarizes the characteristics of each of the included studies. We evaluated the quality of all included studies, which indicated that the studies have high quality and low risk of bias, as shown in Figure 2.

Figure 1.

Figure 1

Open in a new tab

Flow chart of study identification and selection.

Table 1.

Baseline characteristics of the included studies and methodological assessment.

Authors Study period Countries Study design Maternal participants Infant participants
Vaccine/Placebo Vaccine/Placebo
Kampmann et al. (27) 2020–2022 18 countries RCT 3,682/3,675 3,568/3,558
Bebia et al. (28) 2019–2021 9 countries RCT 145/68 140/66
Simões et al. (29) 2019–2020 4 countries RCT 327/79 325/78
Lewnard et al. (30) 2015–2018 11 countries RCT 3005/1,573 2,978/1,546
Madhi et al. (31) 2015–2018 87 countries RCT 3,045/1,581 3,008/1,561
Muňoz et al. (32) 2014–2015 8 countries RCT 22/28 22/28
Open in a new tab

Figure 2.

Figure 2

Open in a new tab

Risk of bias summary for the included RCTs (the green color and special symbol “+” represent a low risk of bias, and the yellow color and special symbol “?” represent an unclear risk of bias).

3.1.1. Demographic characteristics of the included studies

There were no statistically significant differences observed between the two groups in terms of age at injection, BMI, gestation at injection, mode of delivery (vaginal/total), gestational age, and infant sex. However, the birth length showed a statistically significant difference (Table 2).

Table 2.

Demographics and clinical characteristics of the included studies.

Outcomes Studies No. of patients WMD or RR 95% CI p-value Heterogeneity
Vaccine/Placebo Chi2 df p-value I2 (%)
Age at injection (years) (1,2,3,5,6) 7,181/5,431 0.06 [−0.14, 0.25] 0.57 0.46 4 0.98 0
Gestational age at birth (2,3,5,6) 3,539/1,755 −0.02 [−0.10, 0.07] 0.70 2.48 3 0.48 0
Gestation at injection (1,3,5) 7,054/5,335 0.00 [−0.11, 0.11] 0.98 0.02 2 0.99 0
BMI (kg/m2) (2,5,6) 3,212/1,677 0.07 [−0.23, 0.37] 0.67 0.39 2 0.82 0
Median Apgar score, 5 min (1,2,5,6) 6,738/5,213 0.13 [−0.22, 0.47] 0.47 11,550.07 3 <0.00001 100
Length (cm) (2,5) 3,148/1,627 −0.20 [−0.38, −0.03] 0.02 0.03 1 0.86 0
Weight (kg) (2,5,6) 3,170/1,655 −0.01 [−0.03,0.02] 0.73 2.54 2 0.28 21
Mode of delivery in study(Vaginal) (2,3,5,6) 2,562/1,266 1.00 [0.97, 1.04] 0.99 4.01 3 0.26 25
Infant Sex (male) (1,2,3,4,5) 5,151/3,456 1.01 [0.98, 1.04] 0.44 3.63 4 0.46 0
Open in a new tab

BMI, body mass index; WMD, weighted mean difference; RR, relative risk; CI, confidence interval.

3.2. Effectiveness of the RSV vaccine

3.2.1. Medically attended lower respiratory tract illness

Data on medically attended lower respiratory tract illness were obtained from four studies involving 16,534 infants (9,858 in the vaccine group and 6,676 in the placebo group) (27, 29–31). A heterogeneity test was conducted on all the included studies, revealing a significant level of heterogeneity (I2 = 82%, p = 0.00008) (Figure 3A). To account for this heterogeneity, a random-effects model was used for combined analysis. The results of the meta-analysis showed that the incidence of lower respiratory tract disease in the vaccine group was significantly lower than that in the placebo group (RR: 0.64; 95% CI: 0.43, 0.96; p = 0.03). No publication bias was observed in the funnel plot and Egger's test (p = 0.217).

Figure 3.

Figure 3

Open in a new tab

Forest plots of perioperative outcomes: (A) medically attended lower respiratory tract illness, (B) medically attended severe lower respiratory tract illness.

3.2.2. Medically attended severe lower respiratory tract illness

An analysis of medically attended severe lower respiratory illness was conducted in three studies involving a total of 12,010 infants (6,880 in the vaccine group and 5,130 in the placebo group) (27, 29, 31). The pooled analysis revealed that the incidence of severe lower respiratory tract disease was significantly lower in the vaccine group compared with that in the placebo group (RR: 0.37; 95% CI: 0.18, 0.79; p = 0.01). However, a significant heterogeneity was observed (I2 = 60%, p = 0.08) (Figure 3B). After excluding the article (31), the heterogeneity test indicated a slight heterogeneity among the studies (I2 = 15%, p = 0.28), suggesting that the heterogeneity shift may be attributed to this specific article. No publication bias was detected in the funnel plot and Egger's test (p = 0.718).

3.2.3. Medically attended lower respiratory tract illness (Day 90/Day 120/Day 150/Day 180)

3.2.3.1. Medically attended lower respiratory tract illness (Day 90)

Two studies involving a total of 11,502 infants (6,475 in the vaccine group and 5,027 in the placebo group) were included in the analysis (27, 31). The pooled analysis indicated that the incidence of lower respiratory tract disease within 90 days was significantly lower in the vaccine group compared with that in the placebo group (RR: 0.30; 95% CI: 0.13, 0.66; p = 0.003). However, there was a significant heterogeneity observed (I2 = 63%, p = 0.10) as shown in Figure 4A. No publication bias was observed based on the funnel plot.

Figure 4.

Figure 4

Open in a new tab

Forest plots of perioperative outcomes: (A) medically attended lower respiratory tract illness (Day 90), (B) medically attended lower respiratory tract illness (Day 120), (C) medically attended lower respiratory tract illness (Day 150), (D) medically attended lower respiratory tract illness (Day 180).

3.2.3.2. Medically attended lower respiratory tract illness (Day 120)

The analysis included two articles on medically attended lower respiratory tract illness (Day 120), which involved a total of 11,502 infants. Among them, 6,475 infants were in the vaccine group and 5,027 were in the placebo group (27, 31). Heterogeneity tests were performed on all the included studies, revealing a significant heterogeneity (I2 = 67%, p = 0.08) (Figure 4B). A random-effects model was used for the combined analysis. The results of the meta-analysis showed that the incidence of lower respiratory tract disease in the 120-day vaccine group was significantly lower than that in the placebo group (RR: 0.39; 95% CI: 0.17, 0.86; p = 0.02). No publication bias was found in the funnel plot.

3.2.3.3. Medically attended lower respiratory tract illness (Day 150)

Two articles were included in the analysis, reporting data on medically attended lower respiratory tract illness at Day 150 for a total of 11,502 infants. Of these, 6,475 were in the vaccine group and 5,027 were in the placebo group (27, 31). The pooled analysis revealed a significantly lower incidence of lower respiratory tract disease in the vaccine group compared with that in the placebo group (RR: 0.40; 95% CI: 0.20, 0.49; p = 0.009), although there was a significant heterogeneity observed (I2 = 61%, p = 0.11) (Figure 4C). No publication bias was detected in the funnel plot.

3.2.3.4. Medically attended lower respiratory tract illness (Day 180)

Data on medically attended lower respiratory tract illness at Day 180 were obtained from two studies involving a total of 11,502 infants (6,475 in the vaccine group and 5,027 in the placebo group) (27, 31). The pooled analysis revealed a significantly lower incidence of lower respiratory tract disease in the vaccine group compared with that in the placebo group (RR: 0.43; 95% CI: 0.21, 0.90; p = 0.02), although there was a significant heterogeneity observed (I2 = 69%, p = 0.07) (Figure 4D). No publication bias was observed in the funnel plot.

3.2.4. Medically attended severe lower respiratory tract illness (Day 90/Day 120/Day 150/Day 180)

3.2.4.1. Medically attended severe lower respiratory tract illness (Day 90)

Three studies were conducted, involving a total of 16,026 infants, with 9,453 in the vaccine group and 6,573 in the placebo group (27, 30, 31). The pooled analysis revealed that the incidence of severe lower respiratory tract disease within 90 days was significantly lower in the vaccine group compared with that in the placebo group (RR: 0.66; 95% CI: 0.44, 1.00; p = 0.05). However, there was a significant heterogeneity observed (I2 = 77%, p = 0.01) as shown in Figure 5A. After excluding one article, the heterogeneity test indicated a slight heterogeneity among the studies (I2 = 12%, p = 0.19), suggesting that the presence of this article might have contributed to the observed heterogeneity. No publication bias was detected in the funnel plot, and the Egger's test showed no significant difference (p = 0.271).

Figure 5.

Figure 5

Open in a new tab

Forest plots of perioperative outcomes: (A) medically attended severe lower respiratory tract illness (Day 90), (B) medically attended severe lower respiratory tract illness (Day 120), (C) medically attended severe lower respiratory tract illness(Day 150), (D) medically attended severe lower respiratory tract illness(Day 180).

3.2.4.2. Medically attended severe lower respiratory tract illness (Day 120)

Two articles reported the data of medically attended severe lower respiratory tract illness (Day 120) in two groups, comprising a total of 11,502 infants (6,475 in the vaccine group and 5,027 in the placebo group) (27, 31). The pooled analysis revealed a significantly lower incidence of severe lower respiratory tract disease in the 120-day vaccine group compared with that in the placebo group (RR: 0.56; 95% CI: 0.33, 0.96; p = 0.03), although there was a significant heterogeneity observed (I2 = 73%, p = 0.06) as shown in Figure 5B. No publication bias was detected in the funnel plot.

3.2.4.3. Medically attended severe lower respiratory tract illness (Day 150)

Two articles were included in the analysis for medically attended severe lower respiratory tract illness at Day 150, involving a total of 11,502 infants (6,475 in the vaccine group and 5,027 in the placebo group) (27, 31). A heterogeneity test was conducted on all the included studies, revealing a significant level of heterogeneity (I2 = 74%, p = 0.05) (Figure 5C). The random-effects model was employed for the combined analysis, and the results of the meta-analysis demonstrated a significantly lower incidence of severe lower respiratory tract disease in the 150-day vaccine group compared with that in the placebo group (RR: 0.61; 95% CI: 0.37, 1.00; p = 0.05). No publication bias was observed in the funnel plot.

3.2.4.4. Medically attended severe lower respiratory tract illness (Day 180)

Data on medically attended severe lower respiratory tract illness at Day 180 were obtained from two studies, involving a total of 11,502 infants (6,475 in the vaccine group and 5,027 in the placebo group) (27, 31). A pooled analysis revealed no significant difference in the incidence of severe lower respiratory tract disease between the vaccine group and the placebo group at 180 days (RR: 0.63; 95% confidence interval: 0.37, 1.07; p = 0.08), although there was a significant heterogeneity observed (I2 = 79%, p = 0.03) (Figure 5D). No publication bias was detected in the funnel plot.

3.3. Vaccine safety (adverse events)

3.3.1. Vaccine safety (adverse events and severe adverse events in the maternal participants)

3.3.1.1. Vaccine safety (adverse events in the maternal participants)

Five studies (27–29, 31, 32) provided data regarding common adverse events among maternal participants in the vaccine and placebo groups. The maternal rates of common adverse events were 43.72% and 32.04%, respectively. The heterogeneity test results (I2 = 35%, p = 0.19) (Figure 6A) indicated that a fixed-effect model was appropriate for merging the data. The merged data showed that the incidence of common adverse events was higher in vaccinated mothers (RR: 1.08; 95% CI: 1.04, 1.12; p < 0.0001). The visual assessment of the plots suggested a mild publication bias, but Egger's test did not show a significant difference (p = 0.253).

Figure 6.

Figure 6

Open in a new tab

Forest plots of perioperative outcomes: (A) adverse events in the maternal participants, (B) severe adverse events in the maternal participants, (C) adverse events in the infant participants, (D) severe adverse events in the infant participants.

3.3.1.2. Vaccine safety (severe adverse events in the maternal participants)

Data on severe adverse events in the maternal participants, including both the vaccine group and the placebo group, were obtained from five studies involving a total of 11,652 participants (7,221 in the vaccine group and 5,431 in the placebo group) (27–29, 31, 32). The pooled analysis revealed no significant difference in the incidence of severe adverse events between the two groups (RR: 1.05; 95% CI: 0.97, 1.15; p = 0.23), and there was no significant heterogeneity observed (I2 = 0%, p = 0.71) (Figure 6B). Furthermore, no publication bias was detected based on the funnel plot and Egger's test (p = 0.347).

3.3.2. Vaccine safety (adverse events and severe adverse events in the infant participants)

3.3.2.1. Vaccine safety (adverse events in the infant participants)

A total of 12,354 infants were included in five studies, with 7,063 in the vaccine group and 5,291 in the placebo group (27–29, 31, 32). The pooled analysis revealed no significant difference in the incidence of common adverse events between the two groups (RR: 1.02; 95% CI: 0.96, 1.10; p = 0.23). However, there was significant heterogeneity (I2 = 55%, p = 0.06) (Figure 6C). After excluding the article (31), the heterogeneity test showed a slight heterogeneity among the studies (I2 = 0%, p = 0.70), suggesting that the heterogeneity shift was related to this article. No publication bias was detected in the funnel plot and Egger's test (p = 0.576).

3.3.2.2. Vaccine safety (severe adverse events in the infant participants)

The data from five articles were analyzed, which reported severe adverse events in the infant participants from the two groups. The study included a total of 12,354 infants, with 7,063 in the vaccine group and 5,291 in the placebo group (27–29, 31, 32). The pooled analysis indicated that there was no significant difference in the incidence of common adverse events between the two groups (RR: 0.98; 95% CI: 0.93, 1.04; p = 0.52), and there was no significant heterogeneity observed (I2 = 0%, p = 0.41) as shown in Figure 6D. The visual assessment of the plots suggested a mild publication bias, but Egger's test did not show a significant difference (p = 0.903).

3.4. Prevention of antimicrobial prescribing in infants

Only one study provided data on the use of antimicrobial prescriptions among infants (30); therefore a meta-analysis was not conducted. In a double-blind trial conducted across 11 countries, infants born to mothers who were randomly assigned to receive an experimental vaccine against RSV showed a 12.9% (95% CI: 1.3%–23.1%) decrease in the incidence of antimicrobial prescribing during the first 3 months of life compared with infants whose mothers received a placebo. The vaccine's efficacy against antimicrobial prescriptions associated with LRTI was 16.9% (95% CI: 1.4%–29.4%). These findings indicate that RSV plays a significant role in the exposure of infants to antimicrobial agents and highlight the potential of effective maternal RSV vaccines in preventing this exposure.

3.5. Sensitivity analysis

We conducted one-way sensitivity analyses to evaluate the influence of each individual study on the combined risk ratio (RR) for common adverse events in infant participants, LRTI, LRTIs, and LRTI (Day 90). By removing the study reported by Madhi et al. (31) in 2020, the pooled analysis of common adverse events in infant participants changed from non-significant to significant (RR: 1.06; 95% CI: 1.01, 1.13; p = 0.03) (Table 3A). On the other hand, when we excluded the study reported by Kampmann et al. in 2023 (1), the pooled analyses for both LRTI and LRTIs changed from significant to non-significant, respectively [RR: 0.76; 95% CI: 0.51, 1.12; p = 0.16 (Table 3B) and RR: 0.31; 95% CI: 0.05, 2.09; p = 0.23 (Table 3C)]. In addition, removing the study reported by Madhi et al. (31) in 2020 caused the pooled analysis of LRTI (Day 90) to change from significant to non-significant (RR: 0.63; 95% CI: 0.32, 1.26; p = 0.19) (Table 3D). In summary, the sensitivity analysis, based on the above metrics, suggests that the results are unstable.

Table 3.

Sensitivity analysis of (A) adverse events in the infant participants, (B) LRTI, (C) LRTIs, and (D) LRTI ((Day 90).

(A)
Study omitted Estimate [95% CI]
Bebia 2023 1.0262862 .95246923 1.105824
Kampmann 2023 .99309498 .96625739 1.020678
Madhi 2020 1.0644673 1.0054245 1.1269774
Muhoz 2019 1.0329605 .95172089 1.1211349
Simöes 2022 1.0201585 .94824064 1.0975308
Combined 1.024568 .9564222 1.0975693
(B)
Study omitted Estimate [95% CI]
Kampmann 2023 .75690234 .51137823 1.1203079
Lewnard 2022 .52508193 .2914046 .946145
Madhi 2020 .54184026 .29532063 .99414283
Simöes 2022 .71188378 .49480492 1.0241985
Combined .63983908 .42624341 .96047009
(C)
Study omitted Estimate [95% CI]
Kampmann 2023 .31476837 .04733396 2.0931931
Madhi 2020 .26214486 .11637959 .59048086
Simöes 2022 .43149492 .20800325 .89511997
Combined .37138573 .17521691 .78718067
(D)
Study omitted Estimate [95%CI]
Kampmann 2023 .83754909 .71285236 .98405862
Lewnard 2022 .54411751 .34558713 .8566981
Madhi 2020 .63125467 .31631967 1.2597462
Combined .66103421 .43840971 .99670746
Open in a new tab

4. Discussion

A total of six articles were included in this meta-analysis, with five of them being randomized controlled trials. The risk of literature bias was found to be low, and the quality score of the included studies was high. This was evident in the proper generation of random sequences, concealment of assignment, blinding, integrity of outcome data, and reporting of the study results. The meta-analysis focused on two main aspects: the effectiveness of maternal RSV vaccination in preventing lower respiratory tract infections in infants and the safety of RSV vaccination in pregnant women.

The results of this meta-analysis indicate that the incidence of lower respiratory tract disease was significantly lower in the vaccine group compared with that in the placebo group. RSV, which is the leading cause of LRTIs in infants and the leading cause of death in infants under 6 months of age, was effectively countered by the vaccine. The study revealed that the vaccine provided a heightened level of protection against LRTIs in infants. Furthermore, it significantly reduced the occurrence of severe lower respiratory tract disease in infants when compared with the placebo group. These findings suggest that maternal vaccination could be the most effective strategy for safeguarding infants at a young age.

To investigate the duration of vaccine efficacy, we conducted a meta-analysis on the incidence of LRTI in infants and the occurrence of severe lower respiratory tract infection at different time intervals (90, 120, 150, and 180 days). The findings of this meta-analysis revealed that there was no significant disparity in the occurrence of severe lower respiratory tract disease between the vaccine group and the placebo group at 180 days. However, when comparing different time intervals, the vaccine group exhibited a significantly effective protective effect compared with the placebo group, particularly within the first 150 days after birth, especially against LRTIs.

Furthermore, this meta-analysis found no noteworthy difference in serious adverse reactions between the vaccine and placebo groups. Nonetheless, there was a significant disparity in the occurrence of common side effects such as local swelling, pain, and numbness. The vaccinated mothers experienced a higher incidence of these side effects, but they were mostly transient and mild. Importantly, the occurrence of severe adverse events in mothers was similar between the vaccine and placebo groups, with no statistically significant difference. Overall, this analysis suggests that the vaccine is both safe and reliable.

Only one study included in this analysis reported data on antibiotic prescribing in infants following maternal RSV vaccination. The study suggests that RSV is a significant factor in infant antimicrobial use and provides evidence that RSV infection can be effectively prevented by maternal RSV vaccination.

Research on RSV vaccines has made rapid and groundbreaking progress in recent years due to a deep understanding of the immune mechanisms of RSV and the application of structural immunology to antigen design (33–35). The main target protein for developing RSV vaccines in recent years is the RSV membrane surface protein F (36, 37). This protein, classified as a Class I membrane protein, undergoes a significant conformational transition from Pre-F to Post-F conformations during the process of mediating viral membrane fusion, thereby completing the early infection process of the virus (19, 38–41). In the 1960s, the first generation of RSV vaccines used an all-virus inactivation strategy called FI-RSV (42–46). However, the administration of this vaccine to infants and young children did not elicit a protective response and instead resulted to an enhanced respiratory disease (ERD) following subsequent respiratory infections, leading to two infant deaths (47–49). The successful resolution of the Pre-F structure in 2013 provided a new target for developing RSV vaccine. Since then, Pre-F has become the main target protein for developing RSV vaccine, leading to a rapid increase in the number of vaccine development strategies and types (50–53). The experimental vaccines included in this meta-analysis were all designed based on Pre-F, and subunit vaccines based on Pre-F are currently considered to be among the most promising vaccine candidates.

This meta-analysis has several limitations. Firstly, the inclusion of a limited number of articles and the variation in vaccine types and doses across studies may introduce heterogeneity in the results, potentially impacting the overall findings. Future large-scale studies are needed to further investigate and validate these findings. Secondly, the results of the study may be influenced by the diversity of races and regions in the included studies. Therefore, it is necessary to conduct regional and ethnic classification studies. Lastly, there was a scarcity of literature regarding the outcome indicators of lower respiratory tract infectious diseases in infants during each time period analyzed.

5. Conclusions

Based on current clinical evidence, this meta-analysis suggests that the efficacy and safety of the RSV vaccine in pregnant women compared with placebo is positive. However, the existing clinical data only assess the efficacy of the vaccine in preventing RSV infection within a single RSV season, and the vaccine's ability to provide protection across several seasons remains uncertain. Further studies are needed to investigate safety issues. With advancements in molecular virology, immunology, and structural biology, the immunological mechanisms of RSV infection and the molecular properties of RSV are becoming clearer. It is anticipated that there will be significant progress in RSV vaccine research and development in the coming years. Maternal vaccination is believed to be the most effective strategy in protecting infants and newborns.

Maternal RSV vaccination has been shown to be effective in preventing lower respiratory tract infections in postpartum infants, with the greatest efficacy observed within the first 150 days of life. Therefore, the administration of RSV vaccination is considered a safe and effective immunization strategy.

Funding Statement

The author(s) declare financial support was received for the research, authorship, and/or publication of this article.

National Key Research and Development Program of China (2022YFC2704803).

Author contributions

JM: Writing – original draft, Writing – review & editing, Data curation, Formal Analysis. LC: Software, Writing – original draft. ST: Writing – review & editing, Software. YS: Writing – review & editing, Conceptualization, Data curation, Writing – original draft.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fped.2023.1260740/full#supplementary-material

The following supporting information can be downloaded at: www.mdpi.com/xxx/s1, Supplementary Figures S1–S5: search details.

Table1.docx (315.8KB, docx)

References

  • 1.Benítez-Guerra D, Piña-Flores C, Zamora-López M, Escalante-Padrón F, Lima-Rogel V, González-Ortiz AM, et al. Respiratory syncytial virus acute respiratory infection-associated hospitalizations in preterm Mexican infants: a cohort study. Influenza Other Respir Viruses. (2020) 14:182–8. 10.1111/irv.12708 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Staebler S, Blake S. Respiratory syncytial virus disease: immunoprophylaxis policy review and public health concerns in preterm and young infants. Policy Polit Nurs Pract. (2021) 22:41–50. 10.1177/1527154420965543 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Chida-Nagai A, Sato H, Sato I, Shiraishi M, Sasaki D, Izumi G, et al. Risk factors for hospitalisation due to respiratory syncytial virus infection in children receiving prophylactic palivizumab. Eur J Pediatr. (2022) 181:539–47. 10.1007/s00431-021-04216-7 [DOI] [PubMed] [Google Scholar]
  • 4.Gonzales T, Bergamasco A, Cristarella T, Goyer C, Wojdyla M, Oladapo A, et al. Effectiveness and safety of palivizumab for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus: a systematic review. Am J Perinatol. (2023) 18:1990–2633. 10.1055/a-1990-2633 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Man WH, Scheltema NM, Clerc M, van Houten MA, Nibbelke EE, Achten NB, et al. Infant respiratory syncytial virus prophylaxis and nasopharyngeal microbiota until 6 years of life: a subanalysis of the MAKI randomised controlled trial. Lancet Respir Med. (2020) 8:1022–31. 10.1016/s2213-2600(19)30470-9 [DOI] [PubMed] [Google Scholar]
  • 6.Ratti C, Greca AD, Bertoncelli D, Rubini M, Tchana B. Prophylaxis protects infants with congenital heart disease from severe forms of RSV infection: an Italian observational retrospective study: palivizumab prophylaxis in children with congenital heart disease. Ital J Pediatr. (2023) 49:4. 10.1186/s13052-022-01399-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Vakrilova L, Nikolova SH, Slavov S, Radulova P, Slancheva B. An outbreak of RSV infections in a neonatology clinic during the RSV-season. BMC Pediatr. (2021) 21:567. 10.1186/s12887-021-03053-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Jun S, Sebastianski M, Featherstone R, Robinson J. Palivizumab and prevention of childhood respiratory syncytial viral infection: protocol for a systematic review and meta-analysis of breakthrough infections. BMJ Open. (2019) 9:e029832. 10.1136/bmjopen-2019-029832 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Kamori A, Morooka Y, Yamamura K, Chong PF, Kuga N, Takahata Y, et al. Effect of delayed palivizumab administration on respiratory syncytial virus infection-related hospitalisation: a retrospective, observational study. Medicine (Baltimore). (2021) 100:e27952. 10.1097/md.0000000000027952 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Piñeros JG, De la Hoz-Valle J, Galvis C, Celis A, Ovalle O, Sandoval CC, et al. Effectiveness of palivizumab immunoprophylaxis in infants with respiratory syncytial virus disease in Colombia. J Infect Dev Ctries. (2021) 15:1708–13. 10.3855/jidc.12561 [DOI] [PubMed] [Google Scholar]
  • 11.Mazur NI, Terstappen J, Baral R, Bardají A, Beutels P, Buchholz UJ, et al. Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape. Lancet Infect Dis. (2023) 23:e2–21. 10.1016/s1473-3099(22)00291-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Schwarz TF, McPhee RA, Launay O, Leroux-Roels G, Talli J, Picciolato M, et al. Immunogenicity and safety of 3 formulations of a respiratory syncytial virus candidate vaccine in nonpregnant women: a phase 2, randomized trial. J Infect Dis. (2019) 220:1816–25. 10.1093/infdis/jiz395 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Walsh EE, Falsey AR, Scott DA, Gurtman A, Zareba AM, Jansen KU, et al. A randomized phase 1/2 study of a respiratory syncytial virus prefusion F vaccine. J Infect Dis. (2022) 225:1357–66. 10.1093/infdis/jiab612 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Buchy P, Badur S. Who and when to vaccinate against influenza. Int J Infect Dis. (2020) 93:375–87. 10.1016/j.ijid.2020.02.040 [DOI] [PubMed] [Google Scholar]
  • 15.Laurie L, Lambert SB, Jones L, Boddy G, O'Grady KF. Influenza and pertussis vaccine uptake during pregnancy among Australian women in south-east Queensland, Australia. Aust N Z J Public Health. (2021) 45:443–8. 10.1111/1753-6405.13133 [DOI] [PubMed] [Google Scholar]
  • 16.Male V. SARS-CoV-2 infection and COVID-19 vaccination in pregnancy. Nat Rev Immunol. (2022) 22:277–82. 10.1038/s41577-022-00703-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Savvidou M. Vaccines and pregnancy. BJOG. (2023) 130:323–4. 10.1111/1471-0528.17405 [DOI] [PubMed] [Google Scholar]
  • 18.Phase 3 clinical trial results for nirsevimab: is it time to consider population-level RSV immunoprophylaxis? J Paediatr Child Health. (2022) 58:1117–8. 10.1111/jpc.15999 [DOI] [PubMed] [Google Scholar]
  • 19.Blunck BN, Rezende W, Piedra PA. Profile of respiratory syncytial virus prefusogenic fusion protein nanoparticle vaccine. Expert Rev Vaccines. (2021) 20:351–64. 10.1080/14760584.2021.1903877 [DOI] [PubMed] [Google Scholar]
  • 20.Cunningham CK, Karron RA, Muresan P, Kelly MS, McFarland EJ, Perlowski C, et al. Evaluation of recombinant live-attenuated respiratory syncytial virus (RSV) vaccines RSV/ΔNS2/Δ1313/I1314l and RSV/276 in RSV-seronegative children. J Infect Dis. (2022) 226:2069–78. 10.1093/infdis/jiac253 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Díez-Domingo J, Sáez-Llorens X, Rodriguez-Weber MA, Epalza C, Chatterjee A, Chiu CH, et al. Safety and immunogenicity of a ChAd155-vectored respiratory syncytial virus (RSV) vaccine in healthy RSV-seropositive children 12–23 months of age. J Infect Dis. (2023) 227:1293–302. 10.1093/infdis/jiac481 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Baraldi E, Checcucci Lisi G, Costantino C, Heinrichs JH, Manzoni P, Riccò M, et al. RSV Disease in infants and young children: can we see a brighter future? Hum Vaccin Immunother. (2022) 18:2079322. 10.1080/21645515.2022.2079322 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Blanco JCG, Cullen LM, Kamali A, Sylla FYD, Chinmoun Z, Boukhvalova MS, et al. Correlative outcomes of maternal immunization against RSV in cotton rats. Hum Vaccin Immunother. (2022) 18:2148499. 10.1080/21645515.2022.2148499 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Blanco JCG, Fernando LR, Zhang W, Kamali A, Boukhvalova MS, McGinnes-Cullen L, et al. Alternative virus-like particle-associated prefusion F proteins as maternal vaccines for respiratory syncytial virus. J Virol. (2019) 93:00914–19. 10.1128/jvi.00914-19 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. (2009) 6:e1000097. 10.1371/journal.pmed.1000097 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Cumpston MS, McKenzie JE, Welch VA, Brennan SE. Strengthening systematic reviews in public health: guidance in the cochrane handbook for systematic reviews of interventions, 2nd edition. J Public Health. (2022) 44:e588–92. 10.1093/pubmed/fdac036 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Kampmann B, Madhi SA, Munjal I, Simões EAF, Pahud BA, Llapur C, et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med. (2023) 388:1451–64. 10.1056/NEJMoa2216480 [DOI] [PubMed] [Google Scholar]
  • 28.Bebia Z, Reyes O, Jeanfreau R, Kantele A, De Leon RG, García Sánchez M, et al. Safety and immunogenicity of an investigational respiratory syncytial virus vaccine (RSVPreF3) in mothers and their infants: a phase 2 randomized trial. J Infect Dis. (2023) 228:299–310. 10.1093/infdis/jiad024 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Simões EAF, Center KJ, Tita ATN, Swanson KA, Radley D, Houghton J, et al. Prefusion F protein-based respiratory syncytial virus immunization in pregnancy. N Engl J Med. (2022) 386:1615–26. 10.1056/NEJMoa2106062 [DOI] [PubMed] [Google Scholar]
  • 30.Lewnard JA, Fries LF, Cho I, Chen J, Laxminarayan R. Prevention of antimicrobial prescribing among infants following maternal vaccination against respiratory syncytial virus. Proc Natl Acad Sci U S A. (2022) 119:e2112410119. 10.1073/pnas.2112410119 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Madhi SA, Polack FP, Piedra PA, Munoz FM, Trenholme AA, Simões EAF, et al. Respiratory syncytial virus vaccination during pregnancy and effects in infants. N Engl J Med. (2020) 383:426–39. 10.1056/NEJMoa1908380 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Muňoz FM, Swamy GK, Hickman SP, Agrawal S, Piedra PA, Glenn GM, et al. Safety and immunogenicity of a respiratory syncytial virus fusion (F) protein nanoparticle vaccine in healthy third-trimester pregnant women and their infants. J Infect Dis. (2019) 220:1802–15. 10.1093/infdis/jiz390 [DOI] [PubMed] [Google Scholar]
  • 33.Ektare V, Lang J, Choi Y, Finelli L. The clinical impact of multiple prevention strategies for respiratory syncytial virus infections in infants and high-risk toddlers in the United States. Vaccine. (2022) 40:6064–73. 10.1016/j.vaccine.2022.08.011 [DOI] [PubMed] [Google Scholar]
  • 34.Garegnani L, Styrmisdóttir L, Roson Rodriguez P, Escobar Liquitay CM, Esteban I, Franco JV. Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children. Cochrane Database Syst Rev. (2021) 11:Cd013757. 10.1002/14651858.CD013757.pub2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Falsey AR, Williams K, Gymnopoulou E, Bart S, Ervin J, Bastian AR, et al. Efficacy and safety of an Ad26.RSV.preF-RSV preF protein vaccine in older adults. N Engl J Med. (2023) 388:609–20. 10.1056/NEJMoa2207566 [DOI] [PubMed] [Google Scholar]
  • 36.Leroux-Roels I, Davis MG, Steenackers K, Essink B, Vandermeulen C, Fogarty C, et al. Safety and immunogenicity of a respiratory syncytial virus prefusion F (RSVPreF3) candidate vaccine in older adults: phase 1/2 randomized clinical trial. J Infect Dis. (2023) 227:761–72. 10.1093/infdis/jiac327 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Nam HH, Ison MG. Respiratory syncytial virus infection in adults. BMJ (Clin Res ed.). (2019) 366:l5021. 10.1136/bmj.l5021 [DOI] [PubMed] [Google Scholar]
  • 38.Blunck BN, Aideyan L, Ye X, Avadhanula V, Ferlic-Stark L, Zechiedrich L, et al. A prospective surveillance study on the kinetics of the humoral immune response to the respiratory syncytial virus fusion protein in adults in Houston, Texas. Vaccine. (2021) 39:1248–56. 10.1016/j.vaccine.2021.01.045 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Che Y, Gribenko AV, Song X, Handke LD, Efferen KS, Tompkins K, et al. Rational design of a highly immunogenic prefusion-stabilized F glycoprotein antigen for a respiratory syncytial virus vaccine. Sci Transl Med. (2023) 15:eade6422. 10.1126/scitranslmed.ade6422 [DOI] [PubMed] [Google Scholar]
  • 40.Cullen LM, Boukhvalova MS, Blanco JCG, Morrison TG. Comparisons of antibody populations in different pre-fusion F VLP-immunized cotton rat dams and their offspring. Vaccines (Basel). (2020) 8:133. 10.3390/vaccines8010133 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Eichinger KM, Kosanovich JL, Gidwani SV, Zomback A, Lipp MA, Perkins TN, et al. Prefusion RSV F immunization elicits Th2-mediated lung pathology in mice when formulated with a Th2 (but not a Th1/Th2-balanced) adjuvant despite complete viral protection. Front Immunol. (2020) 11:1673. 10.3389/fimmu.2020.01673 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Eichinger KM, Kosanovich JL, Lipp MA, Perkins TN, Petrovsky N, Marshall C, et al. Maternal immunization with adjuvanted RSV prefusion F protein effectively protects offspring from RSV challenge and alters innate and T cell immunity. Vaccine. (2020) 38:7885–91. 10.1016/j.vaccine.2020.10.065 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Ha B, Yang JE, Chen X, Jadhao SJ, Wright ER, Anderson LJ. Two RSV platforms for G, F, or G + F proteins VLPs. Viruses. (2020) 12:906. 10.3390/v12090906 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Harshbarger W, Abeyrathne PD, Tian S, Huang Y, Chandramouli S, Bottomley MJ, et al. Improved epitope resolution of the prefusion trimer-specific antibody AM14 bound to the RSV F glycoprotein. mAbs. (2021) 13:1955812. 10.1080/19420862.2021.1955812 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Kwon YM, Lee Y, Kim KH, Jung YJ, Li Z, Jeeva S, et al. Antigenicity and immunogenicity of unique prefusion-mimic F proteins presented on enveloped virus-like particles. Vaccine. (2019) 37:6656–64. 10.1016/j.vaccine.2019.09.041 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Liang B, Matsuoka Y, Le Nouën C, Liu X, Herbert R, Swerczek J, et al. A parainfluenza virus vector expressing the respiratory syncytial virus (RSV) prefusion F protein is more effective than RSV for boosting a primary immunization with RSV. J Virol. (2020) 95:e01512–20. 10.1128/jvi.01512-20 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Mazur NI, Higgins D, Nunes MC, Melero JA, Langedijk AC, Horsley N, et al. The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. Lancet Infect Dis. (2018) 18:e295–311. 10.1016/s1473-3099(18)30292-5 [DOI] [PubMed] [Google Scholar]
  • 48.Mazur NI, Horsley NM, Englund JA, Nederend M, Magaret A, Kumar A, et al. Breast milk prefusion F immunoglobulin G as a correlate of protection against respiratory syncytial virus acute respiratory illness. J Infect Dis. (2019) 219:59–67. 10.1093/infdis/jiy477 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.McGinnes Cullen L, Luo B, Wen Z, Zhang L, Durr E, Morrison TG. The respiratory syncytial virus (RSV) G protein enhances the immune responses to the RSV F protein in an enveloped virus-like particle vaccine candidate. J Virol. (2023) 97:e0190022. 10.1128/jvi.01900-22 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Essink B, Sabharwal C, Cannon K, Frenck R, Lal H, Xu X, et al. Pivotal phase 3 randomized clinical trial of the safety, tolerability, and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults aged ≥18 years. Clin Infect Dis. (2022) 75:390–8. 10.1093/cid/ciab990 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Gilbert BE, Patel N, Lu H, Liu Y, Guebre-Xabier M, Piedra PA, et al. Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge. Vaccine. (2018) 36:8069–78. 10.1016/j.vaccine.2018.10.073 [DOI] [PubMed] [Google Scholar]
  • 52.Hodgson D, Koltai M, Krauer F, Flasche S, Jit M, Atkins KE. Optimal respiratory syncytial virus intervention programmes using Nirsevimab in England and Wales. Vaccine. (2022) 40:7151–7. 10.1016/j.vaccine.2022.10.041 [DOI] [PubMed] [Google Scholar]
  • 53.Leroux-Roels G, De Boever F, Maes C, Nguyen TL, Baker S, Gonzalez Lopez A. Safety and immunogenicity of a respiratory syncytial virus fusion glycoprotein F subunit vaccine in healthy adults: results of a phase 1, randomized, observer-blind, controlled, dosage-escalation study. Vaccine. (2019) 37:2694–703. 10.1016/j.vaccine.2019.04.011 [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Table1.docx (315.8KB, docx)

Articles from Frontiers in Pediatrics are provided here courtesy of Frontiers Media SA

RESOURCES